This is the authors' abstract. We don't add key points for this paper.
Salient findings of the fourth serological survey of SARS-CoV-2 infections conducted among the age cohort above 10 years in Tamil Nadu (India) have been described. The overall seroprevalence of 87% was reported in the survey done in December 2021, whereas in the first, second, and third surveys, the seropositivity was 32%, 29%, and 70%, respectively. The % share of the antibodies formed due to vaccination in the third and fourth surveys have the contributions of 6.2% and 28.3%, respectively as per the vaccination record of the state since the above given proportion of the state’s population (full population) was fully vaccinated (two-dose) by the time the two surveys were conducted. Age-wise break up of seropositivity of the fourth survey showed that the cohort of 10-18 years had the least (68.4%) seroprevalence and adults above 60 had the highest at 84.5%. The rate of the spread of the virus decreased due to the hybrid immunity developed by infection and vaccination. Using the vaccination and serological data, the % enhancement of the antibodies formed due to vaccination has been worked out in the real world on the ground.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Shervani et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: